66 results
424B3
COEP
Coeptis Therapeutics Holdings Inc
26 Mar 24
Prospectus supplement
6:30am
impact of our acquisitions, business strategy, and strategic priorities. These statements involve known and unknown risks, uncertainties and other … strategy on a timely basis or at all;
We may have difficulties managing our anticipated growth, or we may not grow at all;
We have a history of losses
424B3
COEP
Coeptis Therapeutics Holdings Inc
26 Mar 24
Prospectus supplement
6:30am
regarding future developments, operations and financial conditions, and the anticipated impact of our acquisitions, business strategy, and strategic … coronavirus known as COVID-19;
We may not be able to successfully implement our growth strategy on a timely basis or at all;
We may have difficulties
424B3
bq4x ps3ik9
15 Dec 23
Prospectus supplement
6:12pm
8-K
EX-99.1
d18yp2zv8unbjh
5 Dec 23
Regulation FD Disclosure
4:30pm
424B3
yly3 5h1vczcz
30 Nov 23
Prospectus supplement
5:00pm
424B3
6juzn9ldv it4i15db
26 Sep 23
Prospectus supplement
4:01pm
8-K
EX-10.1
me881atjirau3c2ah
22 Aug 23
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
4:01pm
8-K
EX-10.2
tg0og49riubdruxznhua
22 Aug 23
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
4:01pm
424B4
v6e6s
15 Jun 23
Prospectus supplement with pricing info
9:25am